Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Rizvi

Internal Medicine Oklahoma City, OK Medical Doctor

NPI 1528175619 CMS profile 114283

4201 S Western Ave, Oklahoma City, OK 73109

Open in the dashboard

General payments

$5,705

380 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Syed Rizvi of Oklahoma City, OK is reported in the CMS Open Payments database as having received $5,705 across 380 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $171 8
2024 General $869 54
2023 General $756 51
2022 General $803 49
2021 General $1,112 76
2020 General $654 39
2019 General $1,340 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Rizvi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Syed Rizvi were reported at $171. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Syed Rizvi Internal Medicine median Middle half National median
2019 $1,340 $159 $48–$570 $163
2020 $654 $119 $33–$402 $114
2021 $1,112 $135 $37–$521 $132
2022 $803 $141 $42–$496 $149
2023 $756 $149 $45–$519 $160
2024 $869 $154 $47–$537 $164
2025 $171 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,664 161 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $768 51 payments
  3. Gilead Sciences, Inc. $552 46 payments
  4. Janssen Biotech, Inc. $308 25 payments
  5. Celgene Corporation $275 21 payments
  6. Pfizer Inc. $148 12 payments
  7. Genzyme Corporation $137 8 payments
  8. QOL Medical, LLC $123 9 payments
  9. Ironwood Pharmaceuticals, Inc $122 7 payments
  10. Ardelyx, Inc. $106 7 payments
  11. Other $503 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,649 378 payments
  2. Education $56 2 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $868 51 payments
  2. RINVOQ $686 42 payments
  3. SKYRIZI $560 35 payments
  4. ENTYVIO Internal Medicine $433 26 payments
  5. MAVYRET $365 22 payments
  6. CREON $359 21 payments
  7. LINZESS $336 22 payments
  8. STELARA $279 23 payments
  9. ZEPOSIA $261 20 payments
  10. Entyvio Lower GI $213 15 payments
  11. Other $1,628 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,497

Median for Gastroenterology: 569

Drug cost

$139,586

Median for Gastroenterology: $104,976

Branded share of claims

38.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 52 $62,644
Linzess Linaclotide Brand 43 $35,557
Mesalamine Generic 37 $8,192
Famotidine Generic 304 $6,297
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 276 $5,983
Mesalamine Er Mesalamine Brand 23 $4,737
Lubiprostone Generic 47 $4,056
Omeprazole Generic 255 $2,936
Colestipol Hcl Generic 38 $2,007
Sucralfate Generic 103 $1,242

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$94,538

Medicare's payments for the services billed

Medicare patients

497

Average age 73

Services billed

1,144

265 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 52%
Diabetes 47%
Chronic kidney disease 38%
Heart failure 37%
Atrial fibrillation 32%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $201
$201 — —
SKYRIZI
  • AbbVie, Inc. $151
$151 — —
DUPIXENT
  • GENZYME CORPORATION $54
  • Regeneron Healthcare Solutions, Inc. $19
$72 — —
ZEPOSIA
  • Celgene Corporation $69
$69 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record